ICH GCP R3 is now in English & EU languages. Book Now
  • Clinical PracticeClinical PracticeRight Arrow
  • PharmacovigilancePharmacovigilanceRight Arrow
  • ManufacturingManufacturingRight Arrow
  • Laboratory PracticeLaboratory PracticeRight Arrow
  • DistributionDistributionRight Arrow
  • MDRMDRRight Arrow
  • AI ClinicalAI ClinicalRight Arrow
Clinical Practice
Pharmacovigilance
Manufacturing
Laboratory Practice
Distribution
MDR
AI Clinical

About

Stay ahead with the latest ICH GCP E6 (R3) training—now tailored for the US clinical research landscape. This updated course brings you everything you need to understand and apply the new R3 principles while aligning with FDA regulations and US research practices. Whether you’re an investigator, study coordinator, or part of a sponsor team, this course helps you conduct ethical, high-quality, and compliant clinical trials.
Learn how R3 strengthens data integrity, risk-based quality management, and participant protection, with practical examples relevant to US-based studies.

Course Syllabus

  1. TheThe History of GCP: Part 1
  2. The History of GCP: Part 2
  3. The History of GCP: Part 3
  4. The History of GCP: Part 4
  5. What is GCP?
  6. The Principles of ICH GCP: Part 1
  7. The Principles of ICH GCP: Part 2
  8. Additional Learning Points
  9. Documentation and Version Control
  10. Quality Assurance (QA)
  11. Key Resources: Part 1
  12. Key Resources: Part 2

  1. Introduction: Part 1
  2. Introduction: Part 2
  3. Introduction: Part 3
  4. Introduction: Part 4
  5. Introduction: Part 5
  6. Introduction: Part 6
  7. Introduction: Part 7
  8. Introduction: Part 8
  9. Introduction: Part 9
  10. Responsibilities of the Regulatory Authority
  11. Responsibilities of the IEC
  12. Subject Informed Consent Forms (ICF) Part 1
  13. Subject Informed Consent Forms (ICF): Part 2
  14. Composition, Functions, Operations, Procedures, and Records
  15. IEC Interactions with Sponsors and Investigators

  1. Introduction
  2. Investigator Responsibilities
  3. Investigator Qualifications and Agreements
  4. Adequate Resources
  5. Medical Care of Trial Subjects: Part 1
  6. Medical Care of Trial Subjects: Part 2
  7. Communication with IRB/IEC
  8. Compliance with the Protocol
  9. Investigational Medicinal Products
  10. Randomisation Procedures and Un-blinding
  11. Informed Consent: Introduction
  12. Informed Consent: The Consent Discussion
  13. Informed Consent: Subjects Who Cannot Read or Write
  14. Informed Consent: Minors and “Mentally Incompetent” Subjects
  15. Informed Consent: Incapacitated Subjects
  16. Informed Consent: Updating Consent
  17. Records and Reports: Introduction
  18. Records and Reports: Study Site Files
  19. Records and Reports: Updates & Amendments
  20. Records and Reports: Source Documents
  21. Records and Reports: Financial Information
  22. Records and Reports: The Case Record Form
  23. Records and Reports: Recording Subject Data
  24. Premature Termination or Suspension of a Trial
  25. Progress Reports and Final Reports by Investigator
  26. Investigator Responsibilities

  1. Introduction: Part 1
  2. Introduction: Part 2
  3. Introduction: Part 3
  4. Quality Management: Part 1
  5. Quality Management: Part 2
  6. Quality Management Part 3
  7. QA and QC (Quality Assurance and Quality Control): Introduction
  8. QA and QC (Quality Assurance and Quality Control): Standard Operating Procedures
  9. QA and QC (Quality Assurance and Quality Control): Agreements & Contracts
  10. Contract Research Organisations
  11. Trial Design
  12. Trial Management: Introduction
  13. Trial Management: Data Management
  14. Trial Management: Electronic Data
  15. Trial Management: Record Keeping
  16. Investigator Selection: Introduction
  17. Investigator Selection: Permissions
  18. Investigator Selection: Responsibilities
  19. Investigator Selection: Compensation
  20. Financing
  21. Notification/ Submission to Regulatory Authorities
  22. Confirmation of Review by IRB/IEC
  23. Information on IMP
  24. Manufacturing, Packaging, Labelling, and Coding Investigational Products: Part 1
  25. Manufacturing, Packaging, Labelling, and Coding Investigational Products: Part 2
  26. Supplying and Handling Investigational Products
  27. Record Access
  28. Data Handling I
  29. Data Handling II
  30. Data Handling III
  31. Data Handling IV
  32. Data Handling V
  33. Data Handling VI
  34. Statistical Programming and Data Analysis I
  35. Statistical Programming and Data Analysis II
  36. Record Keeping and Retention
  37. Audit and Inspection
  38. Noncompliance
  39. Premature Termination or Suspension of a Trial: Part 1
  40. Premature Termination or Suspension of a Trial: Part 2
  41. Clinical Trial/Study Reports
  42. Multicentre Trials

  1. Introduction
  2. Data Governance Part 1
  3. Data Governance Part 2
  4. Maintain the Blind
  5. Data Life Cycle I
  6. Data Life Cycle II
  7. Data Life Cycle III
  8. Data Life Cycle IV
  9. Computerised Systems I
  10. Computerised Systems II
  11. Computerised Systems III
  12. Computerised Systems IV
  13. Computerised Systems V
  14. Computerised Systems VI
  15. Computerised Systems VII

  1. Introduction
  2. Monitor
  3. The Monitoring Visit: Part 1
  4. The Monitoring Visit: Part 2
  5. Verifying IMP
  6. Complying with the Protocol, Amendments, SOP and Guidance
  7. Verifying Informed Consent
  8. The Case Record Form (CRF) and Source Documents
  9. Verifying Subject Data
  10. Closing out the Monitoring Visit
  11. The Monitoring Report & Plan
  12. Quality Management - Centralised Monitoring
  13. Fraud and Misconduct: Part 1
  14. Fraud and Misconduct: Part 2

  1. Introduction
  2. AEs, ADRs, & SUSARs
  3. Serious Adverse Events
  4. SUSARs
  5. Adverse Events of Special Interest
  6. Periodic Safety Reports

  1. Introduction
  2. Protocol Structure and Content: Part 1
  3. Protocol Structure and Content: Part 2
  4. Protocol Structure and Content: Part 3

  1. Introduction
  2. Investigator Brochure Structure and Content

  1. Introductions
  2. Archiving
  3. Documents to be Present Pre-Study
  4. Documents to be Present Post-Study

  1. Regulatory Framework- Key FDA Regulations for Clinical Trials
  2. 21CFR Part 50
  3. 21CFR Part 54
  4. 21CFR Part 312
  5. Comparative Table
  6. IND Application
  7. IRB Oversight
  8. Safety Repoting

  1. Glossary & Abbreviations
  2. EU Guidance Documents
  3. ICH Guidance Documents
  4. US FDA Guidance Documents
  5. Global Competent Authorities List

Course Certificate

On course completion, you receive your official ICH-GCP e6(R3) certification, allowing you to participate in clinical trials internationally
course_certificate_icon

Our Certified Customers

novartis
NHS
takeda
roche
baxter

Learner Rating & Reviews

4.7
★★★★★★
Average Rating
536 global ratings
★★★★★
87.0%
★★★★★
5.0%
★★★★★
3.0%
★★★★★
3.0%
★★★★★
2.0%
RC

Working with Whitehall training for the last two years of partnership has been a very successful experience – I have fast access to all the GCP course...

SM

I have finalised the demo for the ICH-GCP E6 R3 refresher course. Overall, I liked the content and the interface. I also want to thank Whitehall Train...

Frequently Asked Questions

Good Clinical Practice (GCP) training is a vital educational programme designed to arm researchers and clinical trial professionals with essential knowledge of ethical and scientific standards. These standards are crucial for executing high-quality clinical trials. The training encompasses the globally acknowledged guidelines set forth by the International Council for Harmonisation (ICH).

The key objectives of GCP training include:

  • Safeguarding the rights, safety, and welfare of human participants
  • Upholding the accuracy and reliability of data collected during clinical trials
  • Fostering uniform, superior practices across all facets of clinical research

Whitehall Training's Good Clinical Practice Course thoroughly explores these critical areas. Our comprehensive programme equips learners with a robust understanding of GCP principles and their practical implementation in real-world clinical research scenarios. By completing this course, participants gain the necessary skills to conduct clinical trials that meet the highest standards of ethical and scientific rigour.

Absolutely. For those involved in clinical trials, GCP certification isn’t just valuable—it’s essential. But even if you’re not directly participating in trials, obtaining GCP certification offers numerous benefits:

  • It demonstrates your commitment to upholding global research standards
  • Your research gains added credibility and quality assurance
  • You’ll be better equipped to safeguard the rights and wellbeing of study participants
  • Your career opportunities in the clinical research sector may expand significantly

Our Whitehall Training Good Clinical Practice Course goes beyond mere certification. We provide you with practical, hands-on knowledge that you can immediately apply in your professional endeavours. By mastering GCP principles through our course, you’ll be well-prepared to navigate the complexities of clinical research with confidence and expertise.

Good Clinical Practice (GCP) certification is crucial for a broad spectrum of individuals working in clinical research:

  • Lead Researchers and Co-investigators: These are the primary and supporting scientists responsible for overseeing and conducting trials at research facilities.
  • On-site Trial Team: This includes study coordinators, research nurses, and other personnel involved in the day-to-day management of clinical trials.
  • Trial Sponsors and Research Organisations: Professionals who manage the overall planning, commencement, and documentation of clinical studies.
  • Regulatory Bodies: Officials tasked with supervising and assessing trial compliance with established standards.
  • Ethics Committees: Groups responsible for reviewing and approving proposed trial protocols to ensure ethical conduct.
  • University and Research Centre Staff: Individuals ensuring that institutional research aligns with international benchmarks.
  • Researchers Funded by National Health Organisations: All scientists and support staff engaged in publicly funded clinical trials.

Our comprehensive GCP course is designed to meet the needs of this varied audience, offering both universal principles and role-specific guidance. Additionally, it serves as an excellent resource for those aiming to enhance their research capabilities and refine their approach to clinical trial operations. The Whitehall Training Good Clinical Practice Course provides tailored content to address the unique requirements of each of these professional groups, ensuring that all participants gain the knowledge necessary for their specific roles in the clinical research process.

Our Good Clinical Practice (GCP) course is designed to provide comprehensive coverage of the ICH-GCP (E6-R3) international guidelines, ensuring you meet the necessary training requirements for participation in international clinical trials. We offer this course in multiple languages to cater to a diverse audience.

This course serves as a detailed, step-by-step guide to the most recent ICH-GCP (E6-R3) guidelines, making it an indispensable resource for anyone involved in clinical trial management. The content has been meticulously crafted by an industry veteran with over three decades of experience, including a tenure as Research Director at a leading pharmaceutical company.

We’re proud to offer a course that’s accredited by the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom. This accreditation underscores the quality and relevance of our training material. To accommodate our global learners, we’ve made the course available in ten languages: English, German, Bulgarian, French, Italian, Japanese, Polish, Portuguese, Russian, and Spanish. Additionally, we’ve developed region-specific versions tailored to the regulatory frameworks of Australia, the UK, the US, France, Germany, and Latin America.

Our course stands out for its user-friendly design and clear visual presentation. This format allows for easy navigation and reference to the ICH-GCP E6 document. Drawing from the author’s extensive industry experience, the course offers practical insights into the application of GCP principles.

Upon completion, participants can earn 6 Continuing Professional Development (CPD) points, further enhancing the value of this training programme.

Indeed, our GCP course has received certification from the Faculty of Pharmaceutical Medicine at the Royal College of Physicians. This prestigious body, established in 1989, is renowned for its role in setting stringent research standards and serves as the professional membership organisation for pharmaceutical physicians across the United Kingdom.

The certification bestowed upon our course is a testament to its quality and relevance. It signifies that our programme meets exacting industry and academic criteria, providing you with a qualification that is widely acknowledged and respected within the field. By completing this certified course, you can be confident that you’re receiving training that aligns with the most current and rigorous standards in pharmaceutical research and practice.

The price of GCP certification can fluctuate based on several key factors:

  • Endorsement: Has the course received approval from official bodies?
  • Validity: Does the training meet ICH standards, allowing researchers to engage in global clinical studies?
  • Content quality: Is the material current and authored by an industry expert?
  • Duration of access: For how long can students utilise the course materials?

Our Whitehall Training GCP course is priced at £79, reflecting its high value across these areas:

  • Endorsement: The Royal College of Physicians has accredited our course, awarding it 6 CPD points.
  • Validity: Upon completion, researchers are equipped to participate in clinical trials, in line with ICH E6(R3) guidelines.
  • Content quality: Lucy Parker, our GCP specialist with over ten years’ experience leading research at major institutions like the NHS, has crafted the course content.
  • Duration of access: We support ongoing professional development by offering unlimited access to course materials.

For group purchases, we offer a 10% discount when buying 5 licences at checkout. If you’re interested in larger group discounts, please reach out to our team for a tailored quote.